Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

Fig. 1

BRCA1/2-Mutation Status Testing. ABC, advanced breast cancer; BRCA1/2, breast cancer susceptibility gene 1 or 2; HER2–, human epidermal growth factor receptor 2–negative; IPWRA, inverse-probability–weighted regression adjustment. *Includes: not tested; not known to have a BRCA1/2 germline mutation test result; not known to have BRCA1/2 germline and somatic wildtype test results. †Of the total population of 3036 patients, 1239 agreed to participate in the patient-reported outcomes analysis. ‡Patients had all patient-reported outcome and covariate data available for the IPWRA analysis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us